- Home
- DHR vs ABT Comparison
DHR vs ABT Comparison
Compare DHR & ABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DHR | ABT |
|---|---|---|
| Founded | 1969 | 1888 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.7B | 183.3B |
| IPO Year | 2006 | 2006 |
Fundamental Metrics
Financial Performance| Metric | DHR | ABT |
|---|---|---|
| Price | $195.25 | $95.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 20 |
| Target Price | ★ $246.27 | $130.90 |
| AVG Volume (30 Days) | 3.4M | ★ 8.3M |
| Earning Date | 04-21-2026 | 04-16-2026 |
| Dividend Yield | 0.82% | ★ 2.63% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.05 | 3.72 |
| Revenue | $19,893,000,000.00 | ★ $44,328,000,000.00 |
| Revenue This Year | $5.43 | $10.75 |
| Revenue Next Year | $5.74 | $8.10 |
| P/E Ratio | $38.59 | ★ $25.73 |
| Revenue Growth | ★ 8.53 | 5.67 |
| 52 Week Low | $180.03 | $93.92 |
| 52 Week High | $242.80 | $137.49 |
Technical Indicators
Market Signals| Indicator | DHR | ABT |
|---|---|---|
| Relative Strength Index (RSI) | 50.63 | 28.54 |
| Support Level | $192.22 | N/A |
| Resistance Level | $196.50 | $103.84 |
| Average True Range (ATR) | 4.12 | 2.21 |
| MACD | 1.24 | -0.40 |
| Stochastic Oscillator | 65.53 | 16.15 |
Price Performance
Historical ComparisonAbout DHR Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
About ABT Abbott Laboratories
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.